Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (576)	4/6/2000 10:47:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1834

>> First, my reading of the news (and from logical combination) is that Janssen back-up compound isn't from some class as R121919 and covered in DuPont patent. Consequently, Janssen/NBIX back-up program is lagging behind proprietary NBIX in-house program. << You lost me. Janssen licensed, independently, the Dupont technology, correct? I'm lost. I was certain that the Janssen backup was of the same class. >> Second, we do not know what are renewed condition (especially royalty) for back-up program. << We can get some tangental guidance from looking at Silverman's next set of numbers? >> So Janssen may still partner NBIX candidate (if candidate do reach wanted drug characteristics) and continue with ongoing back-up program. << 50:50?? Sure! <g> >> Third, there is open question on CRF-R2 agonist program(urocortin like ligand). << Hey, if one molecule works and a second works better, so be it. Sounds like Vale et al. have NBIX in the lead here, too? If two molecules work better than one.... "ah, heck!" <g> >> This didn't come overnight. It is a very big MINUS for NBIX management. << I hate this.